ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced positive findings from two phase IIa proof-of-concept studies of investigational antiretroviral therapies VH4524184 (VH184) and …

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from two phase IIa proof-of-concept studies of investigational antiretroviral therapies VH4524184 (VH184) …

… that switching to an integrase inhibitor-based antiretroviral regimen increased … studies to determine whether taking integrase inhibitors leads to cardiovascular disease … disease risk, individuals on integrase inhibitor-containing regimens should be closely …

Date: March 5, 2025 Time: 8am EST (US) / 10am BRT (Brazil) / 3pm SAST (South Africa) / 6:30pm IST (India) / 9pm CST (Taiwan) HIV drug resistance (HIVDR) can emerge with use of antiretroviral (ARV) drugs for HIV treatment and prevention. The …

… investigate whether ART, particularly integrase inhibitors, could similarly impact fetal … suggest a possible association between integrase inhibitors and maternal metabolic changes, … growth in patients on integrase inhibitors. While these medications remain …

… failure in the era of integrase inhibitors: a Spanish nationwide cohort. HIV … virological nonsuppression outcomes with initial integrase inhibitor-based regimens: a prospective RESPOND …

… . VH184, the first third-generation integrase inhibitor, with the potential for long … clinical trials of second-generation integrase inhibitors in treatment-experienced people living …

… Health Organization recommended using the integrase inhibitor, dolutegravir (DTG), in first- and … drug resistance to HIV-1 integrase inhibitors, with a focus on dolutegravir … the impact of resistance to integrase inhibitors on both public health and …